Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
SARS-CoV-2-specific T cells generated for adoptive immunotherapy are capable of recognizing multiple SARS-CoV-2 variants.
Panikkar A, Lineburg KE, Raju J, Chew KY, Ambalathingal GR, Rehan S, Swaminathan S, Crooks P, Le Texier L, Beagley L, Best S, Solomon M, Matthews KK, Srihari S, Neller MA, Short KR, Khanna R, Smith C. Panikkar A, et al. Among authors: beagley l. PLoS Pathog. 2022 Feb 14;18(2):e1010339. doi: 10.1371/journal.ppat.1010339. eCollection 2022 Feb. PLoS Pathog. 2022. PMID: 35157735 Free PMC article.
Autologous CMV-specific T cells are a safe adjuvant immunotherapy for primary glioblastoma multiforme.
Smith C, Lineburg KE, Martins JP, Ambalathingal GR, Neller MA, Morrison B, Matthews KK, Rehan S, Crooks P, Panikkar A, Beagley L, Le Texier L, Srihari S, Walker D, Khanna R. Smith C, et al. Among authors: beagley l. J Clin Invest. 2020 Nov 2;130(11):6041-6053. doi: 10.1172/JCI138649. J Clin Invest. 2020. PMID: 32750039 Free PMC article. Clinical Trial.
Pre-emptive and therapeutic adoptive immunotherapy for nasopharyngeal carcinoma: Phenotype and effector function of T cells impact on clinical response.
Smith C, Lee V, Schuessler A, Beagley L, Rehan S, Tsang J, Li V, Tiu R, Smith D, Neller MA, Matthews KK, Gostick E, Price DA, Burrows J, Boyle GM, Chua D, Panizza B, Porceddu SV, Nicholls J, Kwong D, Khanna R. Smith C, et al. Among authors: beagley l. Oncoimmunology. 2017 Jan 4;6(2):e1273311. doi: 10.1080/2162402X.2016.1273311. eCollection 2017. Oncoimmunology. 2017. PMID: 28344888 Free PMC article.
Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial.
Smith C, Beagley L, Rehan S, Neller MA, Crooks P, Solomon M, Holmes-Liew CL, Holmes M, McKenzie SC, Hopkins P, Campbell S, Francis RS, Chambers DC, Khanna R. Smith C, et al. Among authors: beagley l. Clin Infect Dis. 2019 Feb 1;68(4):632-640. doi: 10.1093/cid/ciy549. Clin Infect Dis. 2019. PMID: 29982441 Clinical Trial.
Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis.
Pender MP, Csurhes PA, Smith C, Douglas NL, Neller MA, Matthews KK, Beagley L, Rehan S, Crooks P, Hopkins TJ, Blum S, Green KA, Ioannides ZA, Swayne A, Aftab BT, Hooper KD, Burrows SR, Thompson KM, Coulthard A, Khanna R. Pender MP, et al. Among authors: beagley l. JCI Insight. 2018 Nov 15;3(22):e124714. doi: 10.1172/jci.insight.124714. JCI Insight. 2018. PMID: 30429369 Free PMC article. Clinical Trial.
27 results